Evidence map›Paper›PMID 30613422›Full record

ArticleBMJ global health2018

Appraising the value of evidence generation activities: an HIV modelling study.

Beth Woods, Claire Rothery, Sarah-Jane Anderson, Jeffrey W Eaton, Paul Revill, Timothy B Hallett, Karl Claxton

Abstract read
In one paragraph

Article in BMJ global health, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Beth WoodsCentre for Health Economics, University of York, York, UK.
Claire RotheryCentre for Health Economics, University of York, York, UK.
Sarah-Jane AndersonDepartment of Infectious Disease Epidemiology, Imperial College London, London, UK.
Jeffrey W EatonDepartment of Infectious Disease Epidemiology, Imperial College London, London, UK.
Paul RevillCentre for Health Economics, University of York, York, UK.
Timothy B HallettDepartment of Infectious Disease Epidemiology, Imperial College London, London, UK.
Karl ClaxtonCentre for Health Economics, University of York, York, UK.

Funding

Medical Research Council MR/R015600/1Wellcome Trust
6 · The paper itself

Abstract

introductionThe generation of robust evidence has been emphasised as a priority for global health. Evidence generation spans a wide range of activities including clinical trials, surveillance programmes and health system performance measurement. As resources for healthcare and research are limited, the desirability of research expenditure should be assessed on the same basis as other healthcare resources, that is, the health gains from research must be expected to exceed the health opportunity costs imposed as funds are diverted to research rather than service provision.

methodsWe developed a transmission and costing model to examine the impact of generating additional evidence to reduce uncertainties on the evolution of a generalised HIV epidemic in Zambia.

resultsWe demonstrate three important points. First, we can quantify the value of additional evidence in terms of the health gain it is expected to generate. Second, we can quantify the health opportunity cost imposed by research expenditure. Third, the value of evidence generation depends on the budgetary policies in place for managing HIV resources under uncertainty. Generating evidence to reduce uncertainty is particularly valuable when decision makers are required to strictly adhere to expenditure plans and when transfers of funds across geographies/programmes are restricted.

conclusionBetter evidence can lead to health improvements in the same way as direct delivery of healthcare. Quantitative appraisals of evidence generation activities are important and should reflect the impact of improved evidence on population health, evidence generation costs and budgetary policies in place.

Indexed as

AIDShealth economicshealth policyhealth services researchHIV

Identifiers

PMID30613422
PMCPMC6304099

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.